Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.

@article{Bender2015MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.},
  author={Shawn B. Bender and Vincent G DeMarco and J. P. Torres Padilla and Nathan T Jenkins and Javad Habibi and Mona Garro and Lakshmi Pulakat and Annayya R. Aroor and Iris Z Jaffe and James R. Sowers},
  journal={Hypertension},
  year={2015},
  volume={65 5},
  pages={1082-8}
}
Patients with obesity and diabetes mellitus exhibit a high prevalence of cardiac diastolic dysfunction (DD), an independent predictor of cardiovascular events for which no evidence-based treatment exists. In light of renin-angiotensin-aldosterone system activation in obesity and the cardioprotective action of mineralocorticoid receptor (MR) antagonists in… CONTINUE READING